 |
Minimalna wpłata $50 Ekskluzywna promocja |
Nasz wynik |
0% prowizja |
Are you looking to buy Sage Therapeutics stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:SAGE! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Sage Therapeutics stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Średnia wielkość
520,296 shs
KAPITAŁ RYNKOWY
$4.30 billion
Giełda Papierów Wartościowych
NASDAQ
Proszę kupić te akcje!
|
NAZWA
|
TICKER
|
PRZEMYSŁ
|
SEKTOR
|
VOLUME
|
KUP TERAZ TĘ AKCJĘ
|
|---|---|---|---|---|---|
|
NASDAQ:SAGE
|
Preparaty farmaceutyczne
|
Medyczny
|
5,223 shs
|
Below is a quick guide on how to buy NASDAQ:SAGE stocks safe, fast and around the world in less than five minutes.
Krok 1: Otworzyć rachunek w eToro – eToro is the best broker to buy Sage Therapeutics shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Krok 2: Załadować Państwa ID - Zgodnie z przepisami KYC eToro poprosi Państwa o przesłanie kopii paszportu lub prawa jazdy.
Krok 3: Wpłata środków - Proszę wpłacić trochę pieniędzy na swoje nowo utworzone konto eToro. Mogą Państwo wybrać pomiędzy przelewem bankowym, e-wallet lub kartą debetową/kredytową lub Paypal.
Krok 4: Buy Sage Therapeutics – Search for “”NASDAQ:SAGE”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Sage Therapeutics stocks with 0% commission!.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
18 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Sage Therapeutics stock.
Wall Street analysts have given Sage Therapeutics a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Sage Therapeutics wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
2 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
3 |  | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:SAGE stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Sage Therapeutics stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Sage Therapeutics stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Ponieważ eToro jest platformą regulowaną, musi Pan wypełnić proces KYC, jest to standardowa procedura i zajmuje tylko kilka minut. Musi Pan przedstawić dowód tożsamości ze zdjęciem (paszport, prawo jazdy) oraz dowód adresu (rachunek za media, wyciąg z banku).
Po zarejestrowaniu się i zweryfikowaniu konta, należy wpłacić środki. eToro akceptuje karty kredytowe/debetowe, przelewy bankowe, a także e-wallety. Tak więc niezależnie od Państwa preferencji znajdzie się coś dla Państwa.
Now that you’ve funded your eToro account, just type “NASDAQ:SAGE stocks" w pasku wyszukiwania na górze ekranu i nacisnąć "handel".
All that’s left is to buy some NASDAQ:SAGE stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:SAGE is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Sage Therapeutics stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Sage Therapeutics.
Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, beating the consensus estimate of ($2.30) by $0.27. The biopharmaceutical company earned $1.64 million during the quarter, compared to analysts’ expectations of $1.85 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 63.81% and a negative net margin of 7,706.84%. The business’s revenue was down 54.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.48) EPS.
View Sage Therapeutics’ earnings history.
Sage Therapeutics’ stock was trading at $42.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have increased by 96.3% and is now trading at $83.02.
18 analysts have issued 12-month price objectives for Sage Therapeutics’ shares. Their forecasts range from $28.00 to $135.00. On average, they anticipate Sage Therapeutics’ share price to reach $80.05 in the next twelve months. This suggests that the stock has a possible downside of 3.6%.
View analysts’ price targets for Sage Therapeutics or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:SAGE stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Ponad 95% środków klientów jest przechowywanych w trybie offline, w zimnym magazynie, co jest kluczowe dla każdego brokera, który zarządza Państwa aktywami. Niezależnie od tego, jak bezpieczna ma być platforma, zalecamy stosowanie 2FA, aby dodać dodatkową warstwę bezpieczeństwa do Państwa konta.
eToro oferuje użytkownikom szereg funkcji, aby mogli Państwo jak najszybciej zacząć inwestować. Mają Państwo stosunkowo unikalną funkcję copy trading, która pozwala na uzyskanie pasywnego dochodu poprzez odzwierciedlanie doświadczonych traderów, co pozwala szybko zacząć zarabiać i daje lepsze zrozumienie strategii stosowanych przez profesjonalistów. Dodatkowo eToro umożliwia użytkownikom inwestowanie w zarządzane portfele, przy czym zarządzany portfel to różne podobne aktywa zgrupowane razem, co pozwala na dywersyfikację konta i zmniejsza ewentualne ryzyko. Dla tych, którzy mają już doświadczenie w handlu, mogą Państwo inwestować na rynkach poza akcjami, ponieważ eToro pozwala użytkownikom na handel ETF-ami, towarami, kryptowalutami i indeksami. Jeżeli już inwestują Państwo poza przestrzenią giełdową, może to być bardzo przydatne, ponieważ pozwala to na zarządzanie wszystkimi Państwa inwestycjami w jednym miejscu.
Sage Therapeutics’ management team includes the following people:
Ms. Kimi E. Iguchi, CFO & Treasurer (Age 59, Pay $536.37k)
Mr. Michael Cloonan, Chief Operating Officer (Age 50, Pay $582.75k)
Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 59, Pay $564.84k)
Dr. Jeffrey M. Jonas, Chief Innovation Officer, Chair of the Science & Technology Forum and Director (Age 68, Pay $983.77k)
Dr. Stephen J. Kanes, Chief Medical Officer (Age 56, Pay $580.67k)
Mr. Barry E. Greene, Pres, CEO & Director (Age 58)
Dr. Heinrich Schlieker Ph.D., Sr. VP of Technical Operations
Dr. Albert J. Robichaud, Chief Scientific Officer (Age 60)
Mr. Matthew Calistri, VP of Investor Relations
Ms. Erin E. Lanciani, Sr. VP of People & Organizational Strategy (Age 52)
Some companies that are related to Sage Therapeutics include BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Axon Enterprise (AXON), Dr. Reddy’s Laboratories (RDY), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS) and BridgeBio Pharma (BBIO).
View all of SAGE’s competitors.
CFD są złożonymi instrumentami i wiążą się z wysokim ryzykiem szybkiej utraty pieniędzy z powodu dźwigni finansowej. 68% kont inwestorów detalicznych traci pieniądze przy handlu CFD u tego dostawcy. Powinni Państwo rozważyć, czy rozumieją Państwo, jak działają kontrakty CFD i czy mogą sobie Państwo pozwolić na wysokie ryzyko utraty pieniędzy.
Based on aggregate information from Reportlab watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).
Sage Therapeutics trades on the NASDAQ under the ticker symbol “SAGE.”
Sage Therapeutics’ stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.59%), Victory Capital Management Inc. (1.41%), Jennison Associates LLC (1.08%), First Trust Advisors LP (0.32%), Candriam Luxembourg S.C.A. (0.28%) and California Public Employees Retirement System (0.25%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul.
View institutional ownership trends for Sage Therapeutics.
SAGE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., State of New Jersey Common Pension Fund D, Pinnacle Associates Ltd., Candriam Luxembourg S.C.A., Banque Cantonale Vaudoise, Westside Investment Management Inc., and Pacer Advisors Inc..
View insider buying and selling activity for Sage Therapeutics or view top insider-selling stocks.
1 | | Minimalna wpłata $50 Ekskluzywna promocja | Nasz wynik 10 ★★★★★ | 0% prowizja |
SAGE stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Jennison Associates LLC, California Public Employees Retirement System, Y Intercept Hong Kong Ltd, Exchange Traded Concepts LLC, Comerica Bank, SG Americas Securities LLC, and Arthur M. Cohen & Associates LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Interactive Brokers Review, eToro Review, Przegląd DEGiro, AvaTrade Review, IG Markets Review, IC Markets Review, CMC Markets Review, Admiral Markets Review i wiele innych. Proszę przeczytać jedną z recenzji, aby dowiedzieć się wszystkiego o brokerze i zacząć kupować akcje już teraz.
One share of SAGE stock can currently be purchased for approximately $83.02.
Sage Therapeutics has a market capitalization of $4.32 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis.
Sage Therapeutics employs 675 workers across the globe.
The official website for Sage Therapeutics is www.sagerx.com.
Na Reportlab.org chcemy się upewnić, że mają Państwo wszystkie najbardziej istotne informacje na temat kupno akcji. Przynosimy Państwu najlepsze przewodniki po giełdzie z osobistymi opiniami, informacjami uzupełniającymi, opiniami o platformach, how to's i więcej. Chcą Państwo uzyskać inne informacje? Proszę zajrzeć na stronę Akcje OTC, Akcje NASDAQ, Akcje na NYSE, Akcje LON, Akcje FRA, Akcje ETR, Zapasy EPA, Akcje TSX lub Akcje Amex. Szukam bardziej szczegółowych informacji, takich jak 5g zapasy, akcje biotechnologiczne, akcje złota i inne informacje z naszego Reportlab.
How can you buy Sage Therapeutics stock on the internet?
You can easily buy Sage Therapeutics stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Inną opcją jest skorzystanie z usług regulowanego brokera, jak np. IC Markets lub Interactive Brokers. You can an account with these brokers and start buying or trading NASDAQ:SAGE stocks in a safe and complete environment to trade in.
Where to buy Sage Therapeutics stock?
You will first want to find a licensed broker that supports NASDAQ:SAGE stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:SAGE stocks in a safe and complete environment.
Is NASDAQ:SAGE stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:SAGE stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Sage Therapeutics stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:SAGE is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Sage Therapeutics stock.
How do you trade Sage Therapeutics stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Sage Therapeutics stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:SAGE stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Sage Therapeutics stock?
To sell your NASDAQ:SAGE stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Sage Therapeutics stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:SAGE stock.
Stephen wie wiele o produktach finansowych, a w szczególności pasjonuje się rynkami giełdowymi i ich uczestnikami. Mamy nadzieję, że przedstawione informacje będą dla Państwa pomocne. Coś nie jest całkiem jasne? Proszę zostawić swoje pytania lub komentarze na dole strony.
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ | |
| Nasz wynik ★★★★★ |
Newsletter
Najnowsze wiadomości
| |
Nasz wynik |
0% prowizja |
Dane o akcjach i kryptowalutach w czasie rzeczywistym
Powiadomienia, Porady & Nowości
Best Stocks & Crypto Guides
Recenzje brokerów i giełd online
Reportlab Finance jest stroną czysto informacyjną i w żadnym wypadku nie oznacza doradztwa inwestycyjnego. Wszystkie inwestycje niosą ze sobą ryzyko i mogą Państwo stracić wszystkie swoje inwestycje. Proszę nie inwestować pieniędzy, na których utratę nie mogą sobie Państwo pozwolić.
Reportlab Finance
38 Holburn Lane
Heckfield Green
IP21 0UB
Zjednoczone Królestwo
Copyright © 2022 Reportlab.Finance | Wszystkie prawa zastrzeżone.
